Filing Flows

Filing Flows › Companies › Haemonetics › Timeline

Haemonetics stock timeline

A year of the price with every insider trade, planned sale, earnings report and material 8-K marked

252 sessions+78.6% to $119.93

Haemonetics (HAE) stock rose 79% over the last 252 sessions, to $119.93. On the way it reported 5 quarters, its insiders filed 1 open-market trade, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.

HAE: a year of the stock with every disclosure on itHAE: a year of the stock with every disclosure on it$68.04$89.84$112$133●2025-11-06 · Earnings: beat the EPS estimate by 14.3%▲2025-11-10 · Kroll Mark W bought $99K●2026-02-05 · Earnings: beat the EPS estimate by 4.8%◆2026-05-01 · Directors and officers: departures, appointments, pay●2026-05-07 · Earnings: beat the EPS estimate by 1.4%◆2026-07-28 · Directors and officers: departures, appointments, pay●2026-08-06 · Earnings: beat the EPS estimate by 5.8%●2026-11-05 · Earnings: beat the EPS estimate by 4.6%●Earnings report▲Insider buy◆8-K event2025-11-062026-11-06
Daily closes, Nov 6, 2025 to Nov 6, 2026; hover a mark for the filing.

Each mark, and what followed

DateKindWhatNext session5 sessions21 sessions
Nov 5, 2026EarningsEarnings: beat the EPS estimate by 4.6%−2.6% (+1.9% vs SPY)——
Aug 6, 2026EarningsEarnings: beat the EPS estimate by 5.8%+1.7% (+1.8% vs SPY)+8.8% (+8.5% vs SPY)+20.7% (+20.3% vs SPY)
Jul 28, 20268-KDirectors and officers: departures, appointments, pay+3.4% (+5.0% vs SPY)+3.4% (−0.6% vs SPY)+25.6% (+22.2% vs SPY)
May 7, 2026EarningsEarnings: beat the EPS estimate by 1.4%+3.2% (+3.5% vs SPY)+7.9% (+6.8% vs SPY)+30.3% (+29.8% vs SPY)
May 1, 20268-KDirectors and officers: departures, appointments, pay−6.9% (−6.5% vs SPY)−7.2% (−9.6% vs SPY)+11.3% (+6.1% vs SPY)
Feb 5, 2026EarningsEarnings: beat the EPS estimate by 4.8%−1.4% (−0.2% vs SPY)−13.7% (−14.6% vs SPY)−2.8% (−0.8% vs SPY)
Nov 10, 2025Insider buyKroll Mark W bought $99K+3.0% (+1.5% vs SPY)+7.2% (+7.1% vs SPY)+20.4% (+18.6% vs SPY)
Nov 6, 2025EarningsEarnings: beat the EPS estimate by 14.3%+28.0% (+29.1% vs SPY)+36.6% (+35.7% vs SPY)+50.4% (+49.2% vs SPY)

Insiders’ record here

In the year on the chart, Haemonetics' insiders reported 1 open-market buy ($99K) and 0 sales ($0). Of the 1 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was −20.0% and after a sale —.

Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →

What this kind of 8-K usually did

Item8-KsNext session, medianUp next session21 sessions, medianTypical size
5.02 Directors and officers: departures, appointments, pay39,174−0.1%48%+0.7%±1.4%

Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →

Report card: every quarter against the estimate → Haemonetics: every quarter → Live insider trades →

Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.